Open-Label Extension of other SZ1839 (Iressa) trials
Study identifier:1839IL/0026
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Multi-centre, Open-label Extension trial of treatment with ZD1839 (Iressa) in patients who have been treated in other ZD1839 Clinical Trials and may benefit from continued Monotherapy ZD 1839.
Medical condition
cancer
Phase
Phase 3
Healthy volunteers
No
Study drug
Gefitinib (Iressa)
Sex
All
Actual Enrollment
100
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Feb 2000
Primary Completion Date: -
Study Completion Date: 01 Oct 2003
Study design
Allocation: N/A
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Apr 2009 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
